ascopubs.org

Phase I Trial of MCARH109, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated ...

Phase I Trial of MCARH109, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis The following ...
EurekAlert!

New Reichman University study: Advances in cancer treatment and research: ChiTaRS 8.0 database of chimeric genes launched to facilitate the precise adaptation of treatments to ...

A new study conducted at the Scojen Institute for Synthetic Biology at Reichman University’s Dina Recanati School of Medicine announces the launch of the ChiTaRS 8.0 database, the world’s largest ...
GEN

Dissecting the CAR T-Cell Membrane Using the Proximity Network Assay

Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...

Biomimetic platform developed to enhance CAR T cell therapy against leukemia

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...